BRAF and colorectal cancer: The combination of seeMet 12 and the BRAF inhibitor sorafenib was then assessed as a potential combination strategy, as cMet is often highly overexpressed in colorectal cancers, whereas BRAF mutations are present in approximately 10% of metastatic cases (36).